Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Tumor Immunotherapy01:27

Tumor Immunotherapy

596
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
596
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer Vaccines01:30

Cancer Vaccines

456
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
456

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.

Nature communications·2026
Same author

Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis.

The oncologist·2026
Same author

Fangchinoline derivative LYY-34 suppresses TNBC by inhibiting BLM DNA helicase from unfolding of c-MYC promoter G-quadruplex DNA.

Biochemical pharmacology·2026
Same author

Correction: Navigating drug-drug interactions with apalutamide.

Prostate cancer and prostatic diseases·2026
Same author

The path forward for T cell engagers in patients with prostate cancer.

Journal for immunotherapy of cancer·2026

関連する実験動画

Updated: Aug 2, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

免疫チェックポイント療法 - 現在の見通しと将来の方向

Padmanee Sharma1, Sangeeta Goswami2, Deblina Raychaudhuri3

  • 1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Cell
|April 14, 2023
PubMed
まとめ

免疫チェックポイント療法 (ICT) は長期にわたる癌の治療効果をもたらしますが,反応率は変動します. 免疫的および非免疫的要因を理解することは,患者の選択を最適化し,ICTの有効性を改善するために不可欠です.

キーワード:
CTLA-4 について情報通信技術PD-1 についてPD-L1 について組み合わせバイオマーカー細胞毒性Tリンパ球関連タンパク質4免疫チェックポイント療法免疫関連の有害事象イラースプログラム細胞死タンパク質 1プログラム死亡リガンド 1リバース翻訳

さらに関連する動画

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

511
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

462

関連する実験動画

Last Updated: Aug 2, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

511
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

462

科学分野:

  • 免疫学
  • 腫瘍学
  • ガン 治療

背景:

  • 免疫チェックポイント療法 (ICT) は癌治療に革命を起こし,一部の患者に持続的な反応をもたらしました.
  • 異なる腫瘍タイプにおけるICT応答率の変動は,より良い患者選択戦略を必要とします.
  • ICTの有効性を最大化し,治療に関連する毒性を最小限に抑えるためには,予測可能なバイオマーカーを特定することが不可欠です.

研究 の 目的:

  • ICTに対する反応と抵抗に影響を与える抗腫瘍免疫の生物学的メカニズムをレビューする.
  • 現在の課題とICTの有効性を向上させるための継続的な取り組みについて議論する.
  • ICTを活用した将来の臨床試験と組み合わせ治療の戦略を概説する.

主な方法:

  • 抗腫瘍免疫に焦点を当てた文献レビュー
  • 免疫チェックポイント阻害剤に対する反応と抵抗に影響を与える要因の分析
  • 将来の臨床開発のためのデータの合成.

主要な成果:

  • ICTの結果に影響を与える免疫的および非免疫的要因の詳細な調査
  • 幅広いICTの適用を妨げている主な課題を特定する.
  • 患者選択と組み合わせ治療の最適化のための戦略を提案しました.

結論:

  • 腫瘍に対する免疫に関する包括的な理解は,ICTの進歩に不可欠です.
  • 現在の限界に対処するには,バイオマーカーの発見を含む多面的なアプローチが必要です.
  • 未来の研究は,ICTの恩恵を高めるための組み合わせ戦略と洗練された臨床試験設計に焦点を当てるべきです.